Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
140 Results for "
CSF1R
" in MedChemExpress (MCE) Product Catalog:
Products (140)
140 Results for "CSF1R" in MCE Product Catalog:
183
183 Publications Verification
Referencia número: HY-16749A
No. CAS: 2040295-03-0
Synonyms: PLX-3397 hydrochloride
Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity [1].
183
Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 [1] .
104
104 Cited Publications
Referencia número: HY-114153A
Pureza: 99.88%
Target:
Áreas de investigación:
PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals [1] .
104
104 Cited Publications
Target:
Áreas de investigación:
PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 is an ideal choose for microglia function research in healthy or diseased states. PLX5622 has been verified by MedChemExpress, which demonstrates desirable microglia depletion efficiency in mice. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm [1] .
47
47 Cited Publications
Synonyms: BLZ945 hydrochloride
Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. [1].
47
47 Cited Publications
Synonyms: BLZ945
Target:
Áreas de investigación:
Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research [1] .
14
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [1] .
4
4 Cited Publications
Áreas de investigación:
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
4
4 Cited Publications
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity [1].
3
3
3 Cited Publications
Synonyms: JNJ-40346527; JNJ-527
Target:
Áreas de investigación:
Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively [1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research [1] .
2
2 Cited Publications
Referencia número: HY-P99259
No. CAS: 1613144-80-1
Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody
Target:
Áreas de investigación:
2
2 Cited Publications
Referencia número: HY-P72948
Pureza: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CSF1R; CSF-1R; Prev. FMS; Macrophage Colony Stimulating Factor I Receptor; C-FMS; Colony Stimulating Factor Receptor; CD115; Receptor Protein-Tyrosine Kinase; CSFR; FMS Proto-Oncogene; McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog; BANDDOS; Macrophage Colony-Stimulating Factor 1 Receptor; CSF-1-R; Proto-Oncogene C-Fms; HDLS1; CSF-1 Receptor; FIM2; CD115 Antigen; GPSC; M-CSF-R; HDLS; Colony Stimulating Factor 1 Receptor; Platelet-Derived Growth Factor Receptor-Like Protein
Species:
Human
Source:
HEK293
2
2 Cited Publications
Synonyms: GB002; PK10571
Áreas de investigación:
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension [1] .
1
1 Cited Publications
CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
1
1 Cited Publications
PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively [1].
1
1 Cited Publications
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity [1].
1
1 Cited Publications
Synonyms: M4205; IDRX-42
Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC50s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models [1].
Referencia número: HY-P990125
Target:
Áreas de investigación:
Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Referencia número: HY-P990043
No. CAS: 2733621-19-5
Synonyms: VGL101
Target:
Áreas de investigación:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
